Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05416294
Other study ID # CS014
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 15, 2022
Est. completion date September 30, 2022

Study information

Verified date July 2022
Source DyAnsys, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To study and evaluate the effect of using the Primary Relief PENS treatment as adjuvant analgesia for reducing pain in total knee replacement (TKR) patients.


Description:

It is a common knowledge that total knee replacement (TKR) surgeries produce great deal of pain in the postoperative period. Superior pain relief is justifiably needed and usually provided. In addition to the conventional methods of pain relief such as continuous epidural block, intrathecal adjuvants, femoral nerve block ± sciatic nerve block, transcutaneous electrical nerve stimulation (TENS) and percutaneous electrical neurostimulation (PENS) have been reported effective by various authors. Recently neurostimulation of auricular nerves via the external auricular surface has shown to alleviate pain after caesarian section. Primary Relief® is percutaneous electrical neuro stimulator designed to administer auricular neurostimulation treatment over 240 hours. Stimulation is performed by sending electrical pulses emitted through needles strategically positioned in the ear. The ear provides numerous points for stimulation within a small area Based on the area of pain relief, chosen points are stimulated. Primary Relief is a miniaturized device designed to administer PENS treatment. Use of this device is recommended for pre-operative, intra-operative and post-operative pain therapy as well as for the treatment of chronic pain. An advantage over drug therapy is that it avoids the possible side-effects of analgesics and helps in early mobilization following orthopedic surgeries including total knee replacement (TKR), total hip replacement (THR) and shoulder surgeries. Therefore, this study is being undertaken to assess the effect of Primary Relief ® in augmenting pain relief after TKR surgery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 44
Est. completion date September 30, 2022
Est. primary completion date September 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: Patients undergoing TKR under regional or general anesthesia and femoral nerve block who consent to participate in the study. Exclusion Criteria: - ASA 3 or 4 - Those receiving psychiatric medication - Those with infection at the site of application. The following data will be collected - Intraoperative use of local anesthetics, opioids and other analgesics - Postoperative details as to the time of application of the device. NPRS in both the groups at multiple intervals, on demand analgesic requirement, overall analgesic consumption during the study period, quality of life questionnaire at the end of the study period and relevant postoperative complications will be noted. - Rescue analgesics will be considered for breakthrough pain or NPRS > 4. Intravenous Tramadol 50mg will be the first rescue analgesic and if pain is not relieved with Tramadol, opiods will be considered. Non steroidal anti inflammatory drugs will be considered to supplement the above medications if there is no contraindication and if need arises. - NPRS score will be noted at multiple intervals for 10 days. - Any nausea, vomiting, giddiness, intolerance to the device will also be noted. - During the follow up, quality of life questionnaire would be administered and the result noted. The device will be removed after 10 days of its application. Any redness at the site of application or pain at the site are noted. The study will end with the removal of the device.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Primary Relief
The group will receive PENS treatment using Primary Relief in addition to the multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline) including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
Inactive Primary Relief
The group will receive a sham device with multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline), including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
DyAnsys, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Numerical Pain Rating Scale (NPRS) To evaluate the pain score in the immediate postoperative period. Pain Score with will be measured on a scale (0 = no pain; 10 = worst imaginable pain). 0 - 3 days ; 0,2,4,6,8,10,12,18,24,36,48,60,72 hrs from the time of completion of surgery
Secondary NPRS Numerical Pain Rating Scale score post-mobilization To evaluate the effect of treatment in reducing the average NPRS scores after mobilization. The measurement will record the daily NPRS scores from day three to ten days. 4 - 10 days ; 96,120,144,168,192,216,240 hrs from the time of completion of surgery)
Secondary Total Use of Analgesics and Opioids To evaluate the effect of treatment in reducing the overall analgesic and opioid requirement in the immediate postoperative period. The measurement will record the total dose and number of additional analgesics required during the immediate postoperative period at rest. OVERALL DOSE IN FIRST 3 DAYS & OVERALL DOSE REQUIRED BETWEEN 4 TO 10 DAYS
Secondary KOOS Score The Knee injury and Osteoarthritis Outcome Score ( koos) To assess the effect of treatment in Quality of life during postoperative period, using the knee injury and osteoarthritis outcome score (KOOS) 5 times planned from 0 - 10 day; (i) 24 hrs before Surgery; (ii) 24 Hrs after completion of surgery; (iii) 72 hrs after completion of Surgery; (iv) 120 hrs after completion of Surgery; (v) At the time of device removal -@240 hrs)
See also
  Status Clinical Trial Phase
Completed NCT01226186 - Self Medication With Oral Morphine After Total Knee Arthroplasty. N/A
Terminated NCT01184196 - ChloraPrep Versus Betadine for Elective Knee Replacement Surgery Phase 4
Completed NCT02460172 - Zip® Surgical Skin Closure Device vs. Staples for Skin Closure in Subjects Having Undergone Bilateral Knee Arthroplasty N/A
Not yet recruiting NCT06393075 - The Effectiveness of Combined Care for Knee Replacement Patients N/A
Recruiting NCT06107296 - Early Perioperative Quality Of Recovery After Hip and Knee Arthroplasty: a Retrospective Comparative Cohort Study
Not yet recruiting NCT06407778 - Comparison of High Intensity Strength Training and Muscle Energy Techniques in TKR Patients N/A
Recruiting NCT04152538 - Changes in Quadriceps Muscular Activity in Patients After Total Knee Arthroplasty Compared to Healty Subjects
Terminated NCT03034733 - The Effect of Dexamethasone on Pain After Total Knee Replacement Surgery Phase 4